Biotechnology in Pharmacology

Degree course: 
Corso di Second cycle degree in BIOLOGY APPLIED TO BIOMEDICAL RESEARCH
Academyc year when starting the degree: 
2013/2014
Year: 
2
Academyc year when helding the course: 
2014/2015
Course type: 
Supplementary compulsory subjects
Credits: 
4
Period: 
First Semester
Standard lectures hours: 
32
Detail of lecture’s hours: 
Lesson (32 hours)
Requirements: 

Good knowledge of Molecular Biology and Pharmacology

Assessment: 
Voto Finale

Aims and learning outcomes

This course will provide students with in-depth knowledge on modern drug discovery technologies as well as on application of advanced technologies to pharmacological research.
Students will gain understating of the full potential of biotechnology for the research of new drug candidates as well as of the problems associated with their development.
Finally the course will provide an overview of the different classes of bio-drugs on the market.

Assessment methods
Learning outcomes is assessed by a written examination and an oral interview.
The written examination consists of four questions about biotechnology application to pharmacological research. In the oral interview students present an in-depth report on one of the bio-drugs on the market or at least in clinical trials, and its comparison with traditional drugs. The final score will be the mean of the separate scores obtained in the two test.

Strategies for the identification and development of compounds with pharmacological activity before and after the biotechnological era
New tools for drug research and development:
• knowledge coming from the human genome project
• bioinformatics
• proteomisc
• genomics
• cellular engineering
• animal engineering
Biotecnology as a tool to identify new drug targets
Biotecnology as a tool to screen pharmacologically active compounds
Different classes of bio-drugs on the market:
• drugs acting on DNA: antisense oligonucleotides and PNA
• drugs acting on DNA: anti-gene oligonuceotides, ribozymes, aptamers, decoys
• drugs acting on DNA: siRNA
• first generation protein therapeutics
• second generation protein therapeutics: with enzymatic or regulatory activity
• second generation protein therapeutics: engineered antibodies
• second generation protein therapeutics: vaccines

D.J.A. Crommelin and R.D.Sindelar: "Biotecnologie farmaceutiche." Zanichelli, buti t is old (2004).
Power point presentations and in-depth articles will be provided

Professors